The estimated Net Worth of Stephen G Austin is at least $3.81 Millón dollars as of 16 March 2020. Stephen Austin owns over 72,218 units of Harrow Health stock worth over $3,805,502 and over the last 8 years Stephen sold HROW stock worth over $0.
Sign up
Stephen Austin HROW stock SEC Form 4 insiders trading
Stephen has made over 1 trades of the Harrow Health stock since 2020, according to the Form 4 filled with the SEC. Most recently Stephen exercised 72,218 units of HROW stock worth $2,987,659 on 16 March 2020.
The largest trade Stephen's ever made was exercising 72,218 units of Harrow Health stock on 16 March 2020 worth over $2,987,659. On average, Stephen trades about 14,444 units every 0 days since 2016. As of 16 March 2020 Stephen still owns at least 91,987 units of Harrow Health stock.
You can see the complete history of Stephen Austin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Stephen Austin's mailing address?
Stephen's mailing address filed with the SEC is 12264 El Camino Real #350, San Diego, CA 92130, USA.
Insiders trading at Harrow Health
Over the last 6 years, insiders at Harrow Health have traded over $1,363,111 worth of Harrow Health stock and bought 1,487,560 units worth $12,882,479 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum y Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of $3,323,914. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth $199,400.
What does Harrow Health do?
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
What does Harrow Health's logo look like?
Complete history of Stephen Austin stock trades at Harrow Health
Harrow Health executives and stock owners
Harrow Health executives and other stock owners filed with the SEC include:
-
Mark Baum,
Chief Executive Officer, Director -
Andrew Boll,
Chief Financial Officer, Corporate Secretary -
John Saharek,
President of ImprimisRx -
Mark L. Baum J.D.,
CEO & Chairman -
Andrew R. Boll C.F.A., C.M.A., CFA, CMA,
CFO & Corp. Sec. -
John P. Saharek,
Pres of ImprimisRx -
Richard Lindstrom,
Director -
Robert Kammer,
Independent Chairman of the Board -
Dr. Robert J. Kammer D.D.S.,
Special Advisor -
R. Lawrence Van Horn,
Independent Director -
Teresa Sparks,
Independent Director -
Larry Dillaha,
Chief Medical Officer -
Kim Barratt,
Chief Talent Officer -
Dr. Larry M. Dillaha M.D.,
Chief Medical Officer -
David Moufarrège,
VP of Technology -
Jamie Webb,
Director of Communications & Investor Relations -
Andrew Livingston,
Chief Innovation Officer -
Dr. Dennis E Saadeh Pharm.D.,
Chief of Formulation Strategy -
David Moufarrège,
VP of Technology -
Lauren P Silvernail,
Director -
Stephen G Austin,
Director -
Anthony Principi,
Director -
Management Inc. Opaleye,
10% owner -
Perry J. Sternberg,
Director -
Martin A. Makary,
Director